Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
$0.010.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -52.80% | -25.95% | -22.41% | -32.06% | 26.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.62% | -49.49% | -45.27% | -51.97% | -2.26% |
| Operating Income | 33.62% | 49.49% | 45.27% | 51.97% | 2.26% |
| Income Before Tax | 46.70% | -120.88% | 52.32% | 32.77% | -11.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.70% | -120.88% | 52.32% | 32.77% | -11.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.70% | -120.88% | 52.32% | 32.77% | -11.16% |
| EBIT | 33.62% | 49.49% | 45.27% | 51.97% | 2.26% |
| EBITDA | 33.81% | 49.93% | 45.78% | 52.60% | 2.21% |
| EPS Basic | 67.92% | -22.71% | 73.42% | 61.85% | 21.02% |
| Normalized Basic EPS | 67.92% | -22.76% | 73.42% | 61.85% | 21.02% |
| EPS Diluted | 67.92% | -22.71% | 73.42% | 62.48% | 21.02% |
| Normalized Diluted EPS | 67.92% | -22.76% | 73.42% | 61.85% | 21.02% |
| Average Basic Shares Outstanding | 66.14% | 79.99% | 79.40% | 76.23% | 40.74% |
| Average Diluted Shares Outstanding | 66.14% | 79.99% | 79.40% | 76.23% | 40.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |